Generic Name and Formulations:
Isotretinoin 10mg, 20mg, 30mg, 40mg; caps; contains soy, Vit.E.
Indications for CLARAVIS:
Severe recalcitrant nodular acne unresponsive to conventional therapy (eg, systemic antibiotics).
Take with meals. 0.5–1mg/kg per day in 2 divided doses; treat for 15–20 weeks or less if nodule count reduced by >70%; max 2mg/kg per day. Repeat course only if necessary after at least 2 months drug-free interval.
Pregnancy (Cat.X). Nursing mothers.
Must register patient in iPLEDGE program (see literature for restrictions and stipulations on use). Be fully familiar with drug's toxicity before use. Counsel patient about need for contraception; obtain 2 negative pregnancy tests prior to initiation of drug and monthly thereafter; use 2 effective methods of contraception 1 month before, during, and 1 month after therapy; get written informed consent (see literature). Monitor blood lipids initially and for 1st 4 weeks. History of psychiatric disorders; monitor and discontinue if signs and symptoms develop. Osteoporosis risk (eg, osteomalacia, anorexia nervosa) or risk of metabolic bone disorders. Monitor bone growth, glucose, sed rate, CBC, liver enzymes. Discontinue if visual or auditory disturbances; colitis, pancreatitis or hepatitis symptoms; uncontrolled hypertriglyceridemia, or significant decrease in WBCs occurs. Refer to specialist if papilledema or hearing disturbances occur. Do not donate blood during and for 1 month after therapy. Avoid wax epilation or skin resurfacing during and for 6 months after therapy. Adolescents. Avoid sun, UV light. Reduced tolerance to contact lenses. Max 1/℞.
Avoid tetracyclines (increased risk of pseudotumor cerebri), Vit. A, or alcohol consumption. Avoid St. John's wort with hormonal contraceptives. Low-dose progestin-only contraceptives (ie, minipills) may provide inadequate contraception. Caution with drugs that can disturb bone metabolism (eg, anticonvulsants, systemic corticosteroids).
Dry skin, eyes, nose, mouth, and lips, transient exacerbation of acne, dizziness, drowsiness, headache, abnormal menses, bronchospasm, voice changes, alopecia, epistaxis, flushing, hirsutism, rash, GI disturbances, photosensitivity, abnormal wound healing, depression, psychosis, suicidal ideation, aggression, pseudotumor cerebri, pancreatitis; visual, auditory, or lipid disturbances; hepatotoxicity, glomerulonephritis, inflammatory bowel disease, osteopenia, osteoporosis, hyperostosis, premature epiphyseal closure, reversible corneal opacities, decreased night vision, musculoskeletal symptoms, back/chest pain, blood dyscrasias, glucose intolerance, palpitation, thrombotic disease.
Caps 10mg, 20mg, 40mg—3 x 10, 10 x 10 ℞ packs; 30mg—3 x 10 ℞ packs
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years